Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Building work at the Kennedy Institute of Rheumatology has finished, providing a new third floor that houses additional meeting and collaboration space for data science and offices for the management of clinical trials.

The front entrance to the Kennedy Institute
The completed roof extension provides additional 'dry lab' space for data scientists

"We are delighted to be welcoming our staff and students to the new roof extension. It provides much needed space for writing and collaborative work, and will ensure we can deliver on our mission to expand our data-driven research across inflammatory and degenerative disease."

- Professor Fiona Powrie, Director of the Kennedy Institute 

Let us take you on a tour of our new third floor roof terrace.

Read more about the extension and the strategic plans of the Kennedy. 

Similar stories

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

The Kennedy’s research strongly endorsed following independent review

We recently welcomed our Scientific Advisory Board (SAB) and the Kennedy Trust Scientific Review Board (TSRB) to the Institute to review our current activities and future plans.

A new research computing platform advances the understanding of key biological processes in disease

To respond to advances in technology and try to answer an increasing range of biological questions, the Kennedy Institute has invested in a high-performance computing facility. We speak to Brian Marsden, Associate Professor of Research Informatics at the Kennedy to find out more.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Mathematician boosts data science research at the Kennedy Institute

Welcome to Yang Luo who has joined the Kennedy Institute as the Principal Investigator of the Luo Group. Her lab is leading the investigation into how genetic variations contribute to diseases of the immune system.

NIHR funding for musculoskeletal and inflammatory disease research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients.